Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 20, 2026

  1. Notable: Berobenatide · Urine Leakage and With Obesity or Overweight (VESPER-SUI) Recruitment opened PfizerPhase 3 NCT07932925
  2. Notable: 177Lu-NYM032 Injection · Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruitment opened Norroy Bioscience Co., LTDPhase 3 NCT07795268
  3. Notable: Zigakibart + Atrasentan · Primary IgA Nephropathy Recruitment opened Novartis PharmaceuticalsPhase 3 NCT07850752
  4. Notable: Efgartigimod · Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) Recruitment opened argenxPhase 2 NCT07760818
  5. Notable: Single-agent Therapy of BR113 for Injection · Advanced Solid Tumors Recruitment opened BioRay Pharmaceutical Co., Ltd.Phase 1 NCT07753590
  6. Notable: ABI-6250 · Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function Recruitment opened Assembly BiosciencesPhase 1 NCT07850999
  7. Notable: Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 · IRM Recruitment opened Norroy Bioscience Co., LTDPhase 1 NCT07768306
  8. Notable: Nutritional Supplementation on Actinic Purpura: A Pilot Study Trial status changed: Suspended → Withdrawn Standard Process Inc.Not applicable NCT06840574
  9. Notable: GRACE-DE · Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) Recruitment opened AstraZenecaNot specified NCT07882212
  10. Notable: BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4 Recruitment opened SynchroHealth LLCNot applicable NCT07421648
  11. Notable: Pediatric Sleep Study Recruitment opened Olly, PBCNot applicable NCT07932938
  12. Notable: IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Recruitment opened Shanghai Gynecologic Oncology GroupPhase 1 NCT07674615
  13. Notable: Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy · Atrial Fibrillation Recruitment opened China National Center for Cardiovascular DiseasesNot applicable NCT07762742
  14. Notable: Metabolic Changes Associated With Weight Gain After Treatment of Achalasia Recruitment opened Assaf-Harofeh Medical CenterNot specified NCT07334639
  15. Notable: Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial Recruitment opened Sichuan Cancer Hospital and Research InstitutePhase 2 NCT07775040
  16. Notable: Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery Recruitment opened Mayo ClinicPhase 4 NCT07570940
  17. Notable: Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery Recruitment opened Samsung Medical CenterPhase 4 NCT07397949
  18. Notable: Baricitinib · Cardiac Sarcoidosis Recruitment opened Stanford UniversityPhase 2 NCT06868381
  19. Notable: H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) Recruitment opened UNC Lineberger Comprehensive Cancer CenterPhase 2 NCT07484139
  20. Notable: Tiprelestat Versus Placebo When Added to Standard of Care · Pulmonary Arterial Hypertension (PAH) Enrolling by invitation only Marlene Rabinovitch, MDPhase 2 NCT07601295
  21. Notable: Vaccine (STEMVAC) for Improving Survival · Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden Recruitment opened University of WashingtonPhase 2 NCT07721259
  22. Notable: Hyaluronidase Injections for Sclerodactyly · Scleroderma Recruitment opened Stanford UniversityPhase 2 NCT07916324
  23. Notable: Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery Recruitment opened Sir Mortimer B. Davis - Jewish General HospitalPhase 4 NCT07371728
  24. Notable: Use of A Complex Gut Bacterial Consortium (MITI 001) · Irritable Bowel Syndrome With Diarrhea Recruitment opened Stanford UniversityEarly Phase 1 NCT07238790
  25. Notable: Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women Recruitment opened Ohio State UniversityEarly Phase 1 NCT07894289